BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 23, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analysts Picks & Changes

Analysts Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 11/20 cls
Exelixis Inc. (NASDAQ:EXEL) Merriman Curhan Ford Joe Pantginis Downgrade Neutral (from buy) -7% $6.71
Pantginis also lowered his target to $6-$7 from $7-$8. He doesn't see any "key stock moving catalysts" until the American Society of Clinical Oncology (ASCO) meeting in June 2010. He expects investors to focus on "the company's ability to rein in its significant cash burn." Exelixis has several compounds in the clinic for cancer, including XL184, a spectrum selective kinase inhibitor in Phase III for thyroid cancer.
Genzyme Corp. (NASDAQ:GENZ) Baird Christopher Raymond Price target Neutral...

Read the full 688 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >